ReviewExperimental neurobiology2017
Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis.
Review in Experimental neurobiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Systematic review and rationale of using psychedelics in the treatment of cannabis use disorder.Frontiers in psychiatry · 2023Pooled it
- Substance Use Disorders and the Psychosis Spectrum: Assessment, Clinical Challenges and Management.Journal of clinical medicine · 2026Review
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology.International journal of molecular sciences · 2023Review
- Risk of psychosis in illicit amphetamine users: a 10 year retrospective cohort study.Evidence-based mental health · 2022Article
- The Epigenetics of Psychosis: A Structured Review with Representative Loci.Biomedicines · 2022Review
- Neurobehavioral Differences of Valproate and Risperidone on MK-801 Inducing Acute Hyperlocomotion in Mice.Behavioural neurology · 2022Article
- Substance-Induced Psychoses: An Updated Literature Review.Frontiers in psychiatry · 2021Review
- Animal Models of Psychosis in Alzheimer Disease.The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry · 2020Review
- Combination ofExperimental neurobiology · 2019Article
- Investigation of betaine as a novel psychotherapeutic for schizophrenia.EBioMedicine · 2019Article
- Role of mGlu2 in the 5-HTPsychopharmacology · 2018Article
- Amphetamine Neurotoxicity in PC12 Cells through the PP2A/AKT/GSK3β Pathway.Neurotoxicity research · 2018Article
- The use of antioxidant compounds in the treatment of first psychotic episode: Highlights from preclinical studies.CNS neuroscience & therapeutics · 2018Review
- Pro-psychotic effects of synthetic cannabinoids: interactions with central dopamine, serotonin, and glutamate systems.Drug metabolism reviews · 2018Review
- Repeated Administration of D-Amphetamine Induces Distinct Alterations in Behavior and Metabolite Levels in 129Sv and Bl6 Mouse Strains.Frontiers in neuroscience · 2018Article
- Comparative analysis of MBD-seq and MeDIP-seq and estimation of gene expression changes in a rodent model of schizophrenia.Genomics · 2017Article
- Isoniazid-Induced Psychosis in a Patient with Pulmonary Tuberculosis: A Case Report.Case reports in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Addictive drug use or prescribed medicine abuse can cause psychosis. Some representative symptoms frequently elicited by patients with psychosis are hallucination, anhedonia, and disrupted executive functions. These psychoses are categorized into three classifications of symptoms: positive, negative, and cognitive. The symptoms of DIP are not different from the symptoms of schizophrenia, and it is difficult to distinguish between them. Due to this ambiguity of distinction between the DIP and schizophrenia, the DIP animal model has been frequently used as the schizophrenia animal model. However, although the symptoms may be the same, its causes are clearly different in that DIP is acquired and schizophrenia is heritable. Therefore, in this review, we cover several DIP models such as of amphetamine, PCP/ketamine, scopolamine, and LSD, and then we also address three schizophrenia models through a genetic approach with a new perspective that distinguishes DIP from schizophrenia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.